{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:21:10Z","timestamp":1781101270113,"version":"3.54.1"},"reference-count":29,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Food and Drug Safety","award":["21153MFDS601"],"award-info":[{"award-number":["21153MFDS601"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Multiple myeloma (MM) is associated with high morbidity and mortality, with elevated rates of arterial thrombosis and venous thromboembolism (VTE) and ischemic stroke (IS). We aimed to estimate the incidence of VTE and IS categorized by the VTE risk grade among individuals with MM in Korea. Additionally, we explored the potential of the IMPEDE VTE score as a tool for assessing IS risk in patients with MM. Methods: This retrospective cohort study comprised 37,168 individuals aged \u2265 18 years newly diagnosed with MM between January 2008 and December 2021 using the representative claims database of the Korean population. The risk of the incidence of VTE and IS within 6 months after MM diagnosis was stratified based on high-risk (IMPEDE VTE score \u2265 8) and low-risk (&lt;8) categories. The hazard ratios (HRs) were estimated using Cox proportional hazard models. Results: The VTE incidence was 120.4 per 1000 person-years and IS incidence was 149.3 per 1000 person-years. Statistically significant differences were observed in the cumulative incidence rates of VTE between groups with high and low VTE scores (p &lt; 0.001) and between individuals aged \u2264 65 years (p &lt; 0.001) and those with a Charlson comorbidity index (CCI) \u2265 3 compared to lower scores (p &lt; 0.001). Additionally, the cumulative incidence rate of IS differed significantly across all groups (p &lt; 0.001). The HR for the high-risk group in VTE and IS occurrence was 1.59 (95% CI, 1.26\u20132.00) and 3.47 (95% CI, 2.99\u20134.02), respectively. Conclusions: It is important to screen and manage high-risk groups for the early development of VTE or IS in patients with newly diagnosed MM.<\/jats:p>","DOI":"10.3390\/jcm13102829","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:28:25Z","timestamp":1715592505000},"page":"2829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Risk of Venous Thromboembolism and Ischemic Stroke Stratified by VTE Risk Following Multiple Myeloma: A Korean Population-Based Cohort Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-2429","authenticated-orcid":false,"given":"Hyun Jin","family":"Han","sequence":"first","affiliation":[{"name":"Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea"},{"name":"Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul 02447, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9844-9145","authenticated-orcid":false,"given":"Miryoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul 02447, Republic of Korea"},{"name":"College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8687-2722","authenticated-orcid":false,"given":"Jiyeon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea"},{"name":"Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul 02447, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Sun","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea"},{"name":"Institute of Regulatory Innovation through Science, Kyung Hee University, Seoul 02447, Republic of Korea"},{"name":"College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0049-3848(12)70024-5","article-title":"Risk and management of thrombosis in multiple myeloma","volume":"129","author":"Leebeek","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_3","first-page":"4991","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: A population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"ref_5","first-page":"1181","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: A retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.thromres.2024.02.011","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study","volume":"236","author":"Bao","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_8","unstructured":"Association, A.S. (2024, April 02). Stroke Risk Assessment. Available online: https:\/\/www.stroke.org\/en\/about-stroke\/stroke-risk-factors\/stroke-risk-assessment."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjcard.2018.11.008","article-title":"Relation of venous thromboembolism risk to ischemic stroke risk in hospitalized patients with cancer","volume":"123","author":"Corley","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: Strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J. Korean Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: Development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.15758","article-title":"Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM\/DFCI 2009 cohort","volume":"20","author":"Chalayer","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.32429\/jkshp.2023.40.2.001","article-title":"Stratification of Venous Thromboembolism Risk in Multiple Myeloma and Analysis of the Use of Antithrombotic Agents","volume":"40","author":"Jang","year":"2023","journal-title":"J. Korean Soc. Health-Syst. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients with Multiple Myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12959-023-00534-y","article-title":"Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma","volume":"21","author":"Li","year":"2023","journal-title":"Thromb. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2147\/CLEP.S273853","article-title":"Performance of ICD-10-CM diagnosis codes for identifying acute ischemic stroke in a national health insurance claims database","volume":"12","author":"Hsieh","year":"2020","journal-title":"Clin. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e008864","DOI":"10.1136\/bmjopen-2015-008864","article-title":"Defining venous thromboembolism and measuring its incidence using Swedish health registries: A nationwide pregnancy cohort study","volume":"5","author":"Sultan","year":"2015","journal-title":"BMJ Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide\u2014A systematic review","volume":"141","author":"Bermejo","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/CCO.0b013e3283592331","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"24","author":"Falanga","year":"2012","journal-title":"Curr. Opin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/rth2.12411","article-title":"Venous thromboembolism in multiple myeloma is associated with increased mortality","volume":"4","author":"Schoen","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12185-018-2540-1","article-title":"Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone","volume":"109","author":"Shin","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.21037\/tcr-23-285","article-title":"Prognostic significance of thromboembolism in multiple myeloma: A systematic review and meta-analysis","volume":"12","author":"An","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/hematology.2022000414","article-title":"Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy","volume":"2022","author":"Covut","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/ajh.25658","article-title":"Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score","volume":"95","author":"Chalayer","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11239-023-02817-7","article-title":"Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: A Brazilian historical cohort","volume":"56","author":"Silveira","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hon.2340","article-title":"Risk of stroke in patients with newly diagnosed multiple myeloma: A retrospective cohort study","volume":"35","author":"Lee","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Antipova, D., Eadie, L., Macaden, A., and Wilson, P. (2019). Diagnostic accuracy of clinical tools for assessment of acute stroke: A systematic review. BMC Emerg. Med., 19.","DOI":"10.1186\/s12873-019-0262-1"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/10\/2829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:44:05Z","timestamp":1760107445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/10\/2829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jcm13102829"],"URL":"https:\/\/doi.org\/10.3390\/jcm13102829","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]}}}